Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 382 participants.
Also called NCT07302854
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 382 participants
- Sponsor
- Registry
-
NCT07302854
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07302854. Randomized; single masking; primary purpose treatment. Start 2025-12-30 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Medium Vessel Occlusion
- Acronym
- MeVO-TNK Ⅱ
- Condition
- Acute Ischemic Stroke
- Condition
- Medium Vessel Occlusion
- Intervention (Procedure)
- Intra-arterial Thrombolysis
- Intervention (Drug)
- Standard medical treatment
- Lead sponsor
- Xiang Luo
Record details
- Record id
cardio:ct-nct07302854- Content hash
b6590cac09782e1980f56bc818b51753928570a238e2bb6b311cfe845e540bd3